Immunome has delivered a very strong 178.2% return over the past 3 years, yet recent share price swings and fresh pipeline news now put the focus squarely on whether that kind of move lines up with what its cash flows can justify. With the stock pulling back in recent weeks, investors are starting to ask if the current valuation fairly reflects the cash the business might ultimately generate.
- Over 3 years, Immunome has gained 178.2%. This makes the question of what its cash flows are worth today much more important for anyone looking at the stock now.
- The recent FDA clearance of Immunome’s IND for IM-1340, a potential first in class antibody drug conjugate for solid tumors, can reshape expectations for when and how much cash the pipeline might produce and what funding the company may need along the way.
- Prefer to judge Immunome on book value? See why Immunome's 4.5x P/B tells a different valuation story.
The stock's next move may depend on whether Immunome's current share price lines up with the intrinsic value suggested by its cash flows under a Discounted Cash Flow (DCF) view.
If you are considering Immunome after this IND update, it may be useful to compare its valuation with other healthcare-focused stocks by reviewing 35 healthcare AI stocks
Is Immunome a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach here focuses on what Immunome might produce in future cash that flows back to shareholders. The latest twelve month free cash flow shows an outflow of $219.09 million, and the projections assume the business shifts from cash burn to positive free cash generation over the next decade rather than shrinking.
Analysts feeding into this DCF expect free cash flow to remain negative for several more years before turning positive around the end of the decade, then growing from that base. That path helps explain why the intrinsic value from the model comes out modestly above the current share price of $20.89, since the market still appears to be pricing in a long and uncertain ramp. Because the recent FDA clearance of the IM-1340 IND only starts a Phase 1 study in late 2026, early trial risk and long timelines likely weigh on sentiment even as the DCF credits those future cash flows. Find out what Immunome could be worth using our Discounted Cash Flow (DCF) estimate.
The Immunome Narrative: What Would Justify Today's Price?
Immunome's valuation puzzle only really comes into focus once you see the specific stories investors are effectively telling about its future cash generation, and that is where Simply Wall St Narratives come in on the Community page. Each scenario links its number to a clear view on how Immunome's growth, profitability and risk profile might evolve from here. This gives you something concrete to test and update as new clinical and financial data arrives.
One of the top community narratives on Immunome: 42% undervalued
"FDA acceptance of Immunome’s NDA for varegacestat in desmoid tumors with an April 28, 2027 PDUFA date sets up a potential first commercial product and a new revenue line…"
Discover why this Narrative puts Immunome at 42% undervalued.
One more angle on Immunome that could change the story
Cash flows tell you what Immunome might be worth on paper, but the people steering it and how their pay is structured can heavily influence what actually happens next. See who runs Immunome and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com